- Home
- AQMS vs MYNZ Comparison
AQMS vs MYNZ Comparison
Compare AQMS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQMS | MYNZ |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 8.8M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AQMS | MYNZ |
|---|---|---|
| Price | $5.39 | $1.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $14.00 |
| AVG Volume (30 Days) | 125.1K | ★ 201.8K |
| Earning Date | 11-12-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $550.00 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.37 | $0.92 |
| 52 Week High | $39.40 | $8.20 |
Technical Indicators
Market Signals| Indicator | AQMS | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 50.59 |
| Support Level | $4.62 | $1.09 |
| Resistance Level | $4.98 | $1.35 |
| Average True Range (ATR) | 0.47 | 0.11 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 28.12 | 52.11 |
Price Performance
Historical ComparisonAbout AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.